IAPT REC'S POTIPTO 17 MAR 2006

19555

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S.	APPLICA	TION	<mark>VO. (I</mark>	f known	, see 37	7 CFR	1.8
	4	$\cap$	∸ میں	70 1		<b>\</b>	

10/5/2418 CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PCT/SE2005/000096 28 January 2005 (28.01.2005) 30 January 2004 (30.01.2004) \* TITLE OF INVENTION **HCV NS-3 SERINE PROTEASE INHIBITORS** APPLICANT(S) FOR DO/EO/US Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Susana Ayesa, Bjorn Classon, Lazlo Rakos and Bertil Samuelsson Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2 This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.  $\Box$ The US has been elected (Article 31). 4. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) 5. is attached hereto (required only if not communicated by the International Bureau).  $\boxtimes$ has been communicated by the International Bureau. b.  $\boxtimes$ is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 6. is attached hereto. a. has been previously submitted under 35 U.S.C. 154(d)(4). b. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) 7. are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made.  $\boxtimes$ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10 Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). 11. A copy of the International Search Report (PCT/ISA/210).  $\times$ 12. Items 13 to 23 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14  $\boxtimes$ A FIRST preliminary amendment. 15. A SECOND or SUBSEQUENT preliminary amendment.  $\Box$ 16. Ò 17. A substitute specification. A power of attorney and/or change of address letter. 18. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 19. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 20.

A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).

EV 861633003 US

1

 $\mathbf{X}$ 

Express Mail Label No.

21.

22.

## IAP9 Rec'd PCT/PTO 17 MAR 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/SE2005/000096

19555

23. Other items or information:

ASSIGNEE NAME: MEDIVIR AB

ASSIGNEE ADDRESS: HUDDINGE, SWEDEN

\*Continued from Priority Date Claimed: 19 May 2004 (19.05.2004) and 22 October 2004 (22.10.2004)

						_		
_	fees have been s	<u> </u>	LCULATIONS \$300.00	PTO USE				
24. 🛭 Basic nat	uonai iee				\$300	Ψ	\$300.00	
25. Examina If the written opinio prepared by IPEA/ All other situations	US indicates all c		\$200.00					
					\$200	<b>†</b>		
If the written opinion by IPEA/US Search fee (37 CF as an International Search	indicates all clain R 1.445(a)(2)) ha ational Searching	\$	\$400.00					
previously c	ommunicated to t	ile US by		<i>.</i> .	\$500		·	
TOTAL	OF 24, 25 and	26 =				\$	\$900.00	
Additional fee sequence list listing in an e	e for specification ing in compliance lectronic medium 50 for each additi							
Total Sheets	DATE							
181 - 100 =	81 /50 =	1	2		x \$250.00	\$	\$500.00	
Surcharge of \$130 declaration after t	0.00 for furnishing	any of the	e search fee, examinatior of the national stage (37	fee, CFR	or the oath or 1.492(h)).	\$	\$130.00	
CLAIMS	DATE DATE							
Total claims	70	- 20 =	50	х	\$50.00	\$	\$2,500.00	
Independent clair	ns 2	- 3=	0	×	\$200.00	\$	\$0.00	
MULTIPLE DEPENDENT CLAIMS (if applicable)   → \$360.00							\$360.00	
			OTAL OF ABOVE C			= \$	\$4,390.00	
☐ Applicant cla	aims small entity s	\$	\$0.00					
					SUBTOTAL	= \$	\$4,390.00	
Processing fee o	f \$130.00 for furni	\$	\$0.00					
the earliest claimed priority date (37 CFR 1.492(i)).  TOTAL NATIONAL FEE =							\$4,390.00	
Fee for recording accompanied by	the enclosed ass an appropriate co	\$	\$0.00					
,		= \$	\$4,390.00					
**		Ar	nount to be	\$				
						Ar	nount to be	\$

!AP9 Rec'd PCT/PTO 17 MAR 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a.	×	A check in the amount of \$	\$4,390.00	to cover the above fe	es is enclosed.				
b.		Please charge my Deposit Ac A duplicate copy of this sheet		in the an	nount of \$	to cover the above fees.			
c.	X	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-1013/SSMP . A duplicate copy of this sheet is enclosed.							
d.		Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.							
mı SE	NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.  SEND ALL CORRESPONDENCE TO:								
Customer No. 23389 Scully, Scott, Murphy & Presser, P.C.					SIGNATURE / Mark J. Cohen				
400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343					NAME				
					32,211				
					REGISTRATION NUMBER				
				_	March 17, 20	06			
					DATE				

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)** Docket No. Applicant(s): Asa Rosenquist, et al. 19555 Application No. Filing Date Examiner Customer No. Group Art Unit Unassigned Herewith Unassigned 23389 Unassigned **HCV NS-3 SERINE PROTEASE INHIBITORS** Invention: I hereby certify that the following correspondence: New U.S. Patent Application under 35 U.S.C. 371 (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 17, 2006 (Date) Mark J. Cohen (Typled or Printed Name of Person Mailing Correspondence) 3.7 (Signature of Person Mailing Correspondence) EV 861633003 US ("Express Mail" Mailing Label Number) Note: Each paper must have its own certificate of mailing.